Floatz logo

Anti-Cd30/Cd16A Monoclonal Antibody Afm13

Hodgkin Lymphoma

Affimed GmbHmonoclonal_antibodyPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

149 Active assets in the Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 3BBB
CYCLOSPORIN A
City of Hope Medical Center
Phase 3BBB
Carboplatin
St. Petersburg State Pavlov Medical University
Phase 2BBB
Cytosin-Arabinosid
Therapeutic Advances in Childhood Leukemia Consortium
Phase 3BBB
Everolimus
OHSU Knight Cancer Institute
Phase 2BBB

View all 50 →

Same molecule, other indications

Anti-Cd30/Cd16A Monoclonal Antibody Afm13 is also rated in:

mycosis fungoidesDormant
BB
Indicative ·
69 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
B
Indicative ·
61 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →